MAML3 and rhabdomyosarcoma: PAX3 was the 5′ fusion partner in 29 cases with 3′ partners being FOXO1 fusions identified in alveolar rhabdomyosarcoma cases, MAML3 and NCOA1 fusions in two different biphenotypic sinonasal sarcoma cases.